Avacopan Patent Expiration
Avacopan is Used for treating severe active ANCA-associated vasculitis in adult patients in combination with standard therapy. It was first introduced by Chemocentryx Inc
Avacopan Patents
Given below is the list of patents protecting Avacopan, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tavneos | US11603356 | Amorphous form of a complement component C5a receptor | Nov 27, 2039 | Chemocentryx |
| Tavneos | US11951214 | Capsule formulations | Nov 27, 2039 | Chemocentryx |
| Tavneos | US8906938 | C5aR antagonists | Jan 06, 2034 | Chemocentryx |
| Tavneos | US8445515 | C5aR antagonists | Feb 03, 2031 | Chemocentryx |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Avacopan's patents.
Latest Legal Activities on Avacopan's Patents
Given below is the list recent legal activities going on the following patents of Avacopan.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Term Extension Certificate | 20 Jan, 2026 | US8906938 |
| PARALEGAL OR ELECTRONIC TERMINAL DISCLAIMER APPROVED | 18 Dec, 2025 | US11603356 |
| Terminal Disclaimer Filed | 18 Dec, 2025 | US11603356 |
| Withdrawal of Application for PTE | 01 Dec, 2025 | US8445515 |
| Email Notification | 28 Oct, 2025 | US8445515 |
| Patent eCofC Notification | 28 Oct, 2025 | US8445515 |
| Mail Patent eCofC Notification | 28 Oct, 2025 | US8445515 |
| Recordation of Patent eCertificate of Correction | 28 Oct, 2025 | US8445515 |
| Post Issue Communication - Certificate of Correction | 10 Oct, 2025 | US8445515 |
| Email Notification | 05 Aug, 2025 | US11603356 |
Avacopan's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Avacopan:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Pharmacokinetics Of Emulsified Avacopan Applied By NG Tube | Mayo Clinic | NA |
RECRUITING
(Aug 1, 2026)
| PHASE1 |
| Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV. | Amgen | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE3 |
| A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD) | Amgen | NA |
COMPLETED
(Mar 1, 2026)
| PHASE1 |